Updated:
Palisade Bio, Inc.
Palisade Bio is a clinical-stage biopharma advancing PALI-2108 for ulcerative colitis. Publicly traded, no disclosed family office structure.
Palisade Bio, Inc.
Palisade Bio was formed through the reverse merger of Seneca Biopharma and Leading BioSciences in April 2021, creating a publicly traded entity focused on precision therapies targeting serious gastrointestinal conditions. The company does not disclose any underlying family wealth or single-family office governance; it operates as a conventional biotech issuer. Its scientific foundation leverages validated phosphodiesterase inhibitors, aiming for localized therapeutic action to minimize systemic side effects. The company's lead asset, PALI-2108, is in Phase 1 clinical development as of 2024, targeting moderate-to-severe ulcerative colitis with an oral, gut-restricted prodrug design. Its pipeline also includes PALI-1908, a PDE4 inhibitor for fibrostenotic Crohn's disease. Palisade Bio pursues a standard biopharma capital model, having completed public equity offerings, including a $5.0 million registered direct offering in February 2024, and engaging institutional investors like Armistice Capital. The firm operates without a disclosed permanent capital vehicle, anchoring its duration to its clinical catalysts. Palisade Bio maintains a lean corporate structure typical of a clinical-stage biotech, with headquarters in Carlsbad, California. Financial statements show a concentrated management team, including CEO J.D. Finley and CFO Robert McRae, and a net loss of $12.3 million for the first nine months of 2024, funded by cash reserves of roughly $10.0 million. The company has no reported philanthropic foundation or family-linked adjacent investment vehicles. Structurally, Palisade Bio's most notable differentiator is its status as a publicly reporting entity with no single-family or individual wealth anchor — a biotech platform driven entirely by institutional capital markets and reverse-merger legacy, not a family's therapeutic mandate. Its governance follows standard Nasdaq listing rules, with no disclosed LP-GP architecture or co-investor club typical of single-family investment offices.
General information
Firm type
Asset Manager
Year founded
—
AUM
Undisclosed
Location
Region
—
Country
—
City
—
Corporate office
—
Frequently asked questions
Is Palisade Bio structured as a single-family office or a conventional biotech?
Palisade Bio is a publicly traded clinical-stage biopharmaceutical company (Nasdaq: PALI) and does not operate as a single-family office. It was formed via a reverse merger between Seneca Biopharma and Leading BioSciences in 2021 and is funded through public equity markets, not a single family's capital.
What is Palisade Bio's lead clinical asset?
The lead asset is PALI-2108, an orally administered, colon-activated PDE4 inhibitor prodrug in Phase 1 development for moderate-to-severe ulcerative colitis. Its design aims to deliver localized, gut-restricted therapeutic effect with potentially fewer systemic side effects than systemically absorbed PDE4 inhibitors.
Does Palisade Bio manage any investment vehicles or family capital?
No. Palisade Bio does not disclose management of any family office capital, multi-asset investment vehicles, or external investor funds beyond its own corporate treasury. It is singularly focused on advancing its drug pipeline.
Who makes investment decisions at Palisade Bio?
Corporate strategy and capital allocation decisions are made by the management team and board of directors, led by CEO J.D. Finley, in alignment with Nasdaq listing standards and SEC reporting requirements. There is no disclosed investment committee or single controlling principal.
How is Palisade Bio related to its predecessor companies?
Palisade Bio was created through a reverse merger in which Leading BioSciences merged into the publicly traded Seneca Biopharma in April 2021. The combined entity rebranded as Palisade Bio, inheriting the Nasdaq ticker and the clinical assets from Leading BioSciences' PDE4 inhibitor platform.
What is Palisade Bio's posture on co-investments alongside external GPs?
Palisade Bio has no known posture on co-investments alongside general partners or venture funds because it does not function as a capital allocator or institutional investor. Its treasury is dedicated to internal drug development, not external GP commitments.
Has Palisade Bio received any strategic investment from pharmaceutical partners?
As of public disclosures, Palisade Bio has funded operations primarily through at-the-market equity programs and registered direct offerings, such as the February 2024 $5.0 million raise with a healthcare-focused institutional investor. No pharmaceutical equity investment or collaboration milestone has been publicly finalized.
Profile maintained by Altss using OSINT (open-source intelligence), regulatory filings, licensed data partners, and verified direct submissions. Read the methodology. Last updated: . Continuous refresh with full update cycles at least every 30 days.
Need institutional-grade insight on family offices?
Altss delivers:
Prefer a guided tour?
We’ll walk you through: